Fate Therapeutics, Inc.
General ticker "FATE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $155.3M (TTM average)
Fate Therapeutics, Inc. follows the US Stock Market performance with the rate: 12.1%.
Estimated limits based on current volatility of 4.3%: low 1.02$, high 1.11$
Factors to consider:
- Total employees count: 181 (0.0%) as of 2024
- Top business risk factors: Insufficient funding, Regulatory and compliance, Market competition, Management turnover, Strategic risks and growth management
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.02$, 3.17$]
- 2025-12-31 to 2026-12-31 estimated range: [0.91$, 2.76$]
Financial Metrics affecting the FATE estimates:
- Positive: with PPE of -1.1 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -65.50 <= 0.33
- Positive: Investing cash flow per share per price, % of 6.51 > -0.66
- Positive: Inventory ratio change, % of -2.80 <= -0.75
- Negative: negative Industry operating cash flow (median)
Short-term FATE quotes
Long-term FATE plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $96.30MM | $63.53MM | $13.63MM |
| Operating Expenses | $404.69MM | $254.04MM | $223.91MM |
| Operating Income | $-308.39MM | $-190.51MM | $-210.28MM |
| Non-Operating Income | $26.66MM | $24.55MM | $22.38MM |
| R&D Expense | $320.45MM | $172.60MM | $135.00MM |
| Income(Loss) | $-281.72MM | $-165.96MM | $-187.90MM |
| Profit(Loss)* | $-281.72MM | $-160.93MM | $-186.26MM |
| Stockholders Equity | $483.94MM | $368.42MM | $318.73MM |
| Assets | $705.56MM | $506.22MM | $440.69MM |
| Operating Cash Flow | $-248.21MM | $-132.26MM | $-122.87MM |
| Capital expenditure | $35.57MM | $6.15MM | $0.73MM |
| Investing Cash Flow | $166.75MM | $112.67MM | $12.22MM |
| Financing Cash Flow | $9.21MM | $0.09MM | $99.89MM |
| Earnings Per Share** | $-2.91 | $-1.64 | $-1.64 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.